Metformin-Teva 1000 mg is a potent oral hypoglycemic medication belonging to the biguanide class, specifically engineered for the comprehensive management of Type 2 Diabetes Mellitus (T2DM). This high-strength formulation is indicated for patients where diet and exercise have proven insufficient in regulating blood glucose, particularly those with excess body weight. As a first-line preparation, it is clinically recognized for its ability to reduce diabetes-related complications. Whether utilized as a monotherapy or integrated into complex regimens with insulin or other oral antidiabetics, Metformin-Teva 1000 mg provides a stable foundation for glycemic control in both adults and adolescents over the age of 10.
Each film-coated tablet contains:
Active Substance: Metformin hydrochloride — 1000 mg.
Excipients: Povidone K-30, anhydrous colloidal silicon dioxide, and magnesium stearate.
Coating (White Opadry Y-1-7000): Hypromellose, titanium dioxide (E 171), and macrogol.
Metformin-Teva exerts its antihyperglycemic effects through three primary biological mechanisms:
Hepatic Inhibition: It reduces the liver's production of glucose by suppressing gluconeogenesis and glycogenolysis.
Peripheral Sensitivity: It enhances insulin sensitivity in skeletal muscles, significantly improving the uptake and utilization of glucose from the blood.
Intestinal Modulation: It delays the absorption of glucose within the gastrointestinal tract.
A significant advantage of metformin is that it does not stimulate insulin secretion, thereby avoiding the risk of hyperinsulinemia and associated weight gain. In monotherapy, it does not cause hypoglycemia.
Type 2 Diabetes Mellitus: Management in adults and children aged 10 and older.
First-line Therapy: Preferred for overweight patients to reduce long-term diabetic complications.
Combination Protocols: Frequently paired with insulin or sulfonylureas to achieve better glycemic control.
Hypersensitivity to metformin hydrochloride or any auxiliary ingredients.
Severe Renal Impairment: Glomerular filtration rate (GFR) < 30 ml/min.
Metabolic Acidosis: Including acute lactic acidosis or diabetic ketoacidosis.
Hypoxic Conditions: Decompensated heart failure, respiratory failure, or recent myocardial infarction.
Acute Risks: Dehydration, shock, or severe infectious diseases.
Hepatic/Alcohol Issues: Liver failure, acute alcohol intoxication, or chronic alcoholism.
Adults:
Starting Dose: Usually begins at 500 mg or 850 mg 2–3 times daily.
Titration: The dose is adjusted after 10–15 days based on serum glucose monitoring.
Maximum Dose: 3000 mg per day, typically divided into 3 doses (e.g., three 1000 mg tablets).
Children and Adolescents (10+ Years):
Starting Dose: Usually 500 mg or 850 mg once daily.
Maximum Dose: 2000 mg per day, divided into 2–3 doses.
Meal Integration: Tablets should be taken during or after meals to minimize gastrointestinal discomfort.
Swallowing: High-dose 1000 mg tablets should be swallowed whole with water.
Gastrointestinal (Very Common): Nausea, vomiting, diarrhea, abdominal pain, and loss of appetite, primarily at the start of therapy.
Nervous System: Taste disturbances (metallic taste).
Metabolic: Rare risk of lactic acidosis. Long-term use may cause decreased Vitamin B12 absorption.
Skin: Isolated reports of itching, redness, or hives.
Lactic Acidosis: This is a life-threatening emergency. Risk increases with renal impairment, excessive alcohol, and dehydration. Seek immediate hospital care if severe muscle cramps or weakness occur.
Pregnancy: Switching to insulin is recommended to maintain optimal blood glucose levels and minimize risks to the fetus.
Breastfeeding: Use is not recommended as metformin is excreted in breast milk and safety data is insufficient.
Driving: Safe in monotherapy; however, caution is required when combined with insulin or sulfonylureas due to potential hypoglycemia.
No special temperature storage conditions are required.
Keep out of reach of children at all times.
Shelf Life: 3 years from the date of manufacture.
There are no reviews for this product.